{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:38:17Z","timestamp":1789688297712,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001059","name":"Connecticut Bar Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia & Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jtct.2022.12.021","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T20:25:10Z","timestamp":1672345510000},"page":"259.e1-259.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed\/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4812-5235","authenticated-orcid":false,"given":"Harper","family":"Hubbeling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Alarcon","family":"Tomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-8032","authenticated-orcid":false,"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Ari","family":"Wijetunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1506-4870","authenticated-orcid":false,"given":"Kathryn R.","family":"Tringale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Batlevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-3226","authenticated-orcid":false,"given":"Parastoo","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Hajj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Schoder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Yahalom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1281-5915","authenticated-orcid":false,"given":"Brandon S.","family":"Imber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.12.021_bib0001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.12.021_bib0002","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.12.021_bib0003","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.12.021_bib0004","first-page":"883","article-title":"Novel agents may be preferable to chemotherapy for large B-cell lymphoma progressing after CD19-CAR-T: a multicenter observational study","volume":"138","author":"Alarcon Tomas","year":"2021"},{"key":"10.1016\/j.jtct.2022.12.021_bib0005","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.12.021_bib0006","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtct.2022.12.021_bib0007","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.12.021_bib0008","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.12.021_bib0009","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00277-021-04560-6","article-title":"Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy","volume":"100","author":"Iacoboni","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.12.021_bib0010","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CART-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.12.021_bib0011","first-page":"1189","article-title":"[Roles of PET\/CT in predicting the prognosis of diffuse large B cell lymphoma patients treated with chimeric antigen receptor T cell therapy]","volume":"28","author":"Zheng","year":"2020","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.jtct.2022.12.021_bib0012","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","article-title":"Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma","volume":"25","author":"Wang","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.12.021_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.713577","article-title":"Tumor burden measured by 18F-FDG PET\/CT in predicting efficacy and adverse effects of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphoma","volume":"11","author":"Hong","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2022.12.021_bib0014","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/RLU.0000000000003756","article-title":"Prognostic impact of 18F-FDG PET\/CT in patients with aggressive B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T cells","volume":"46","author":"Sesques","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.jtct.2022.12.021_bib0015","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijrobp.2021.06.038","article-title":"Patterns and predictors of failure in recurrent or refractory large B-cell lymphomas after chimeric antigen receptor T-cell therapy","volume":"111","author":"Figura","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtct.2022.12.021_bib0016","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.12.005","article-title":"Role of radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Ng","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtct.2022.12.021_bib0017","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2022.12.021_bib0018","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210098","article-title":"The current and future role of radiation therapy in the era of CART-cell salvage","volume":"94","author":"DeSelm","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.jtct.2022.12.021_bib0019","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.12.021_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2021-147913","volume":"138","author":"Kamdar","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.12.021_bib0021","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.12.021_bib0022","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation therapy as a bridging strategy for CART cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtct.2022.12.021_bib0023","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging radiation therapy before commercial chimeric antigen receptor T-cell therapy for relapsed or refractory aggressive B-cell lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtct.2022.12.021_bib0024","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2022.12.021_bib0025","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1182\/blood-2019-131449","article-title":"MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy","volume":"134","author":"Imber","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.jtct.2022.12.021_bib0026","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/CJI.0000000000000284","article-title":"Radiation priming chimeric antigen receptor T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma with high tumor burden","volume":"43","author":"Qu","year":"2020","journal-title":"J Immunother"},{"key":"10.1016\/j.jtct.2022.12.021_bib0027","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","article-title":"Current methods to define metabolic tumor volume in positron emission tomography: which one is better?","volume":"52","author":"Im","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.jtct.2022.12.021_bib0028","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.12.021_bib0029","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1148\/radiol.2015142088","article-title":"Imaging for staging and response assessment in lymphoma","volume":"276","author":"Johnson","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.jtct.2022.12.021_bib0030","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.12.021_bib0031","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2021.11.031","article-title":"Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?","volume":"166","author":"Saifi","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtct.2022.12.021_bib0032","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2022.12.021_bib0033","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.12.021_bib0034","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672201870X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672201870X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T17:19:45Z","timestamp":1721668785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672201870X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S266663672201870X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.12.021","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed\/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}